DE60008508D1 - Agglomerate durch kristallisation - Google Patents

Agglomerate durch kristallisation

Info

Publication number
DE60008508D1
DE60008508D1 DE60008508T DE60008508T DE60008508D1 DE 60008508 D1 DE60008508 D1 DE 60008508D1 DE 60008508 T DE60008508 T DE 60008508T DE 60008508 T DE60008508 T DE 60008508T DE 60008508 D1 DE60008508 D1 DE 60008508D1
Authority
DE
Germany
Prior art keywords
crystalization
agglomerate
lactum
agglomerates
solvents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60008508T
Other languages
English (en)
Other versions
DE60008508T9 (de
DE60008508T3 (de
DE60008508T2 (de
Inventor
Johannes Booij
Geertruida Lefferts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centrient Pharmaceuticals Netherlands BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60008508(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of DE60008508D1 publication Critical patent/DE60008508D1/de
Application granted granted Critical
Publication of DE60008508T2 publication Critical patent/DE60008508T2/de
Publication of DE60008508T3 publication Critical patent/DE60008508T3/de
Publication of DE60008508T9 publication Critical patent/DE60008508T9/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
DE60008508T 1999-04-01 2000-04-03 Agglomerate durch kristallisation Active DE60008508T9 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201034 1999-04-01
EP99201034 1999-04-01
EP00917035A EP1165049B2 (de) 1999-04-01 2000-04-03 Agglomerate durch kristallisation
PCT/EP2000/002917 WO2000041478A2 (en) 1999-04-01 2000-04-03 Agglomerates by crystallisation

Publications (4)

Publication Number Publication Date
DE60008508D1 true DE60008508D1 (de) 2004-04-01
DE60008508T2 DE60008508T2 (de) 2004-12-23
DE60008508T3 DE60008508T3 (de) 2012-01-19
DE60008508T9 DE60008508T9 (de) 2012-06-14

Family

ID=8240058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008508T Active DE60008508T9 (de) 1999-04-01 2000-04-03 Agglomerate durch kristallisation

Country Status (12)

Country Link
US (3) US6979735B1 (de)
EP (1) EP1165049B2 (de)
CN (1) CN1209099C (de)
AT (1) ATE260096T1 (de)
AU (1) AU3817300A (de)
CA (1) CA2364342C (de)
DE (1) DE60008508T9 (de)
ES (1) ES2215628T5 (de)
MX (1) MXPA01009808A (de)
SI (1) SI1165049T2 (de)
TR (1) TR200102771T2 (de)
WO (1) WO2000041478A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
DE60108154T2 (de) * 2000-10-20 2005-12-22 Sandoz Ag Pharmazeutische Zubereitungen enthaltend Clavulansäure
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
US20040132712A1 (en) * 2001-04-12 2004-07-08 Otto Damon Pharmaceutical compositions comprising clavulanic acid
AT500131A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Organische verbindungen
AT500132A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Organische verbindungen
AT500134A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
AT500133A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1761457B (zh) * 2003-03-21 2010-05-12 帝斯曼知识产权资产管理有限公司 三水羟氨苄青霉素
CA2552632A1 (en) * 2004-01-06 2005-07-21 Panacea Biotec Ltd. Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
US10130678B2 (en) 2014-12-29 2018-11-20 Bioventus, LLC. Systems and methods for improved delivery of osteoinductive molecules in bone repair
CN108905264A (zh) * 2018-07-17 2018-11-30 凯莱英医药集团（天津）股份有限公司 连续化结晶方法在β-内酰胺类抗生素合成中的应用及连续化结晶系统
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3692781A (en) * 1971-02-26 1972-09-19 Glaxo Lab Ltd Recovery of pure cephalexin from acidic reaction mixtures
US4138555A (en) * 1971-05-14 1979-02-06 Glaxo Laboratories, Limited (6R,7R)-7-[2-aryl-2-(etherified oximino)acetamido]-3-carbamoyloxymethylceph-3-em-4-carboxylic acid 1-oxides
AR206201A1 (es) * 1972-06-29 1976-07-07 Ciba Geigy Ag Procedimiento para la obtencion de compuestos de acido 7beta-amino-3-cefem-3-01-4-carboxilico0-substituidos
US3932386A (en) * 1973-06-18 1976-01-13 American Home Products Corporation Sodium 6-(L-aminocyclohexane carboxamido)penicillanic acid
GB1563103A (en) * 1975-10-13 1980-03-19 Beecham Group Ltd Process for the preparation of clavulanic acid
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4454069A (en) * 1979-08-24 1984-06-12 Beecham Group Limited Clavulanic acid salts and their preparation from the tertiary butyl amine salt
NZ199061A (en) * 1980-12-09 1984-10-19 Beecham Group Ltd 9-(n-tetrazolyl)-deoxyclavulanic acids,salts,esters,and pharmaceutical compositions
US4522701A (en) * 1982-02-11 1985-06-11 E. I. Du Pont De Nemours And Company Process for preparing an anisotropic aromatic pitch
US4456753A (en) * 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
DE3314725A1 (de) * 1983-04-22 1984-10-25 Siemens AG, 1000 Berlin und 8000 München Oberflaechenwellen-resonatorfilter
US4659812A (en) * 1985-08-20 1987-04-21 Bristol-Myers Company Cephalosporin intermediates
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
US5288861A (en) * 1987-01-29 1994-02-22 Beecham Group Plc Potassium clavulanate in rosette form
CA1326486C (en) * 1987-01-29 1994-01-25 Dennis Edward Clark Potassium clavulanate
WO1991000865A1 (en) 1989-07-10 1991-01-24 Gema S.A. A novel stable form of cephradine, process for its production and intermediates used therein
GB9009473D0 (en) 1990-04-27 1990-06-20 Beecham Group Plc Pharmaceutical formulation
RU2043988C1 (ru) * 1991-02-12 1995-09-20 Плива Хандельс ГмбХ 4-оксоазетидин-2-сульфоновые кислоты или их соли в качестве промежуточных продуктов в синтезе бета-лактамовых антибиотиков и способ их получения
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
AT400033B (de) * 1992-03-10 1995-09-25 Biochemie Gmbh Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben
AT401871B (de) † 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
SI9400107A (en) * 1994-03-02 1995-10-31 Lek Tovarna Farmacevtskih New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804.
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4426973C1 (de) * 1994-07-29 1996-03-28 Degussa Verfahren zur Herstellung eines als Brennstoffzellenelektrode einsetzbaren Plattinlegierungskatalysators
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
ZA975198B (en) * 1996-06-13 1997-12-15 Smithkline Beecham Corp Improved process for preparing potassium clavulanate.
US6242006B1 (en) 1996-07-16 2001-06-05 Gist-Brocades B.V. β-lactam granules free of organic solvents
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
EP0937084A1 (de) * 1996-11-11 1999-08-25 Gist-Brocades B.V. Verfahren zur herstellung von clavulansäure-salzen und estern
ATE187498T1 (de) * 1997-03-24 1999-12-15 Cipan Comp Ind Prod Verfahren zur isolierung eines pharmazeutisch verträglichen alkalimetallsalzes der clavulansäure
EP1023065A1 (de) 1997-08-29 2000-08-02 Dsm N.V. Zusatzfreie granulate

Also Published As

Publication number Publication date
DE60008508T9 (de) 2012-06-14
SI1165049T2 (sl) 2011-11-30
ES2215628T3 (es) 2004-10-16
CN1345231A (zh) 2002-04-17
MXPA01009808A (es) 2002-04-24
EP1165049A2 (de) 2002-01-02
EP1165049B2 (de) 2011-07-06
SI1165049T1 (en) 2004-12-31
US20110045082A1 (en) 2011-02-24
TR200102771T2 (tr) 2002-04-22
US20060079496A1 (en) 2006-04-13
US6979735B1 (en) 2005-12-27
DE60008508T3 (de) 2012-01-19
AU3817300A (en) 2000-08-01
CA2364342A1 (en) 2000-07-20
EP1165049B1 (de) 2004-02-25
CN1209099C (zh) 2005-07-06
ES2215628T5 (es) 2011-11-28
CA2364342C (en) 2011-02-01
ATE260096T1 (de) 2004-03-15
DE60008508T2 (de) 2004-12-23
WO2000041478A3 (en) 2000-11-02
WO2000041478A2 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
DE60008508D1 (de) Agglomerate durch kristallisation
WO2002074767A8 (en) Metalloproteinase inhibitors
WO2004078923A3 (en) Pyk2 crystal structure and uses
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO1999054326A8 (de) Dihydropyrimidine
CA2335270A1 (en) Electrochromic media with concentration-enhanced stability, process for the preparation thereof and use in electrochromic devices
DK1537097T3 (da) Fremgangsmåde til fremstilling af 3-Halo-4,5-dihydro-1H-pyrazoler
WO2001017973A3 (de) Neue herbizide
AU5705700A (en) Crystals of benzimidazole compounds
WO2002074752A8 (en) Metalloproteinase inhibitors
EP1020452A4 (de) Benzimidazolderivate
EP1577286A4 (de) Perfluorallyloxyverbindung und diese verbindung enthaltende flüssigkristalline zusammensetzung
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
WO2002083616A1 (fr) DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
EP1555261A4 (de) Valerolactonverbindungen und parf mzusammensetzung
EP1355966B8 (de) Mit aktinischer strahlung aktivierbare blends aus kristallinen und amorphen verbindungen, verfahren zu ihrer herstellung und ihre verwendung
WO2000071553A8 (en) Novel aluminosiloxane compound and process for preparing the same
WO2003029254A1 (fr) Procede de preparation de composes tricycliques
TR200001819T2 (tr) COPD tedavi yöntemi.
YU27099A (sh) Postupak i intermedijari za proizvodnju piridin-2,3- dikarboksilat jedinjenja
DK0532562T3 (da) Fremgangsmåde til fremstilling af 10-g(b)-H-steroider
WO1998034584A3 (en) Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
SE0101323D0 (sv) New process
ITRM20010309A1 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
WO2004004715A3 (en) Novel delta opioid receptor ligands

Legal Events

Date Code Title Description
R102 Epo decision maintaining patent in amended form now final

Ref document number: 1165049

Country of ref document: EP

Effective date: 20110706

R082 Change of representative

Ref document number: 1165049

Country of ref document: EP

Representative=s name: DIEHL & PARTNER GBR, 80333 MUENCHEN, DE

R081 Change of applicant/patentee

Ref document number: 1165049

Country of ref document: EP

Owner name: DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V., NL

Free format text: FORMER OWNER: DSM IP ASSETS B.V., HEERLEN, NL

Effective date: 20120515

R082 Change of representative

Ref document number: 1165049

Country of ref document: EP

Representative=s name: DIEHL & PARTNER GBR, DE

Effective date: 20120515